Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis
Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics. We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-01, Vol.16 (1), p.e0245284-e0245284 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0245284 |
|---|---|
| container_issue | 1 |
| container_start_page | e0245284 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Miyagawa, Hanae Hara, Hiromichi Araya, Jun Minagawa, Shunsuke Numata, Takanori Umezawa, Yoshinori Asahina, Akihiko Nakagawa, Hidemi Kuwano, Kazuyoshi |
| description | Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.
We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT was performed to evaluate DIIP. Serum KL-6 levels were measured before treatment (baseline) and during treatment.
A total of 603 psoriasis patients were treated with anti-IL-17/23 biologics with mean follow-up of 21.1 months. Six patients developed DIIP at mean 14 months after initiation of the therapy. Older age, higher baseline KL-6 value and more frequent pre-existing IPs were associated with development of DIIP by univariate analysis. At the onset of DIIP, elevated serum KL-6 levels with concomitantly increased ground glass opacity (GGO) in Chest CT were demonstrated. DIIP was improved by only cessation of causative agents in five patients but steroid therapy was needed in one patient.
DIIP is a plausible complication of anti-IL-17/23 biologics. Age, baseline KL-6 level and underlying IP could be the risk factors for DIIP development. Serum KL-6 levels and chest CT are useful for not only predicting but also detecting DIIP caused by anti-IL-17/23 biologics. |
| doi_str_mv | 10.1371/journal.pone.0245284 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2476219381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650815042</galeid><doaj_id>oai_doaj_org_article_ce4cb10922864dc4bbbe3b746489e71b</doaj_id><sourcerecordid>A650815042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-41db5658e30862172bcc7392a8e8e6b10a9e9e72e5229ddb509b248d0a80c01f3</originalsourceid><addsrcrecordid>eNqNk1uL1DAUx4so7rr6DUQLguhDZ3Nrmr4Iy-BlYGDB22tI09OZDJ2km6Revr0Zp7tMZR8kDwknv_M_l-Rk2XOMFphW-HLnRm9VvxichQUirCSCPcjOcU1JwQmiD0_OZ9mTEHYIlVRw_jg7o5RhLMrqPGuXW-WVjuBNiEaH3HW5stEUq3WBq0tC88a43m3SVWFsO2poc2MTnuhoVJ8PFsa9s0Ylcz6oaMDGkP80cZsPwXmjgglPs0ed6gM8m_aL7NuH91-Xn4r19cfV8mpdaF6TWDDcNiUvBVAkOMEVabSuaE2UAAG8wUjVUENFoCSkbhOL6oYw0SIlkEa4oxfZy6Pu0LsgpwYFSViV5GoqcCJWR6J1aicHb_bK_5ZOGfnX4PxGKp_60IPUwHSKWRMiOGs1a5oGaFMxzkRKAjdJ690UbWz20OpUuFf9THR-Y81WbtwPWVU1ohVLAm8mAe9uRghR7k3Q0PfKghuPeZdcYFIm9NU_6P3VTdRGpQKM7VyKqw-i8oqXSOASMZKoxT1UWi3sjU6_qTPJPnN4O3NITIRfcaPGEOTqy-f_Z6-_z9nXJ-wWVB-3wfVjNM6GOciOoPYuBA_dXZMxkodhuO2GPAyDnIYhub04faA7p9vfT_8AVHsD7A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476219381</pqid></control><display><type>article</type><title>Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Miyagawa, Hanae ; Hara, Hiromichi ; Araya, Jun ; Minagawa, Shunsuke ; Numata, Takanori ; Umezawa, Yoshinori ; Asahina, Akihiko ; Nakagawa, Hidemi ; Kuwano, Kazuyoshi</creator><contributor>Kuwana, Masataka</contributor><creatorcontrib>Miyagawa, Hanae ; Hara, Hiromichi ; Araya, Jun ; Minagawa, Shunsuke ; Numata, Takanori ; Umezawa, Yoshinori ; Asahina, Akihiko ; Nakagawa, Hidemi ; Kuwano, Kazuyoshi ; Kuwana, Masataka</creatorcontrib><description>Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.
We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT was performed to evaluate DIIP. Serum KL-6 levels were measured before treatment (baseline) and during treatment.
A total of 603 psoriasis patients were treated with anti-IL-17/23 biologics with mean follow-up of 21.1 months. Six patients developed DIIP at mean 14 months after initiation of the therapy. Older age, higher baseline KL-6 value and more frequent pre-existing IPs were associated with development of DIIP by univariate analysis. At the onset of DIIP, elevated serum KL-6 levels with concomitantly increased ground glass opacity (GGO) in Chest CT were demonstrated. DIIP was improved by only cessation of causative agents in five patients but steroid therapy was needed in one patient.
DIIP is a plausible complication of anti-IL-17/23 biologics. Age, baseline KL-6 level and underlying IP could be the risk factors for DIIP development. Serum KL-6 levels and chest CT are useful for not only predicting but also detecting DIIP caused by anti-IL-17/23 biologics.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0245284</identifier><identifier>PMID: 33411857</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Biological products ; Biology and Life Sciences ; Care and treatment ; Chest ; Complications and side effects ; Dermatology ; Disease ; Health risks ; Interleukin 17 ; Internal medicine ; Medical prognosis ; Medical records ; Medicine ; Medicine and Health Sciences ; Monoclonal antibodies ; Opacity ; Patients ; Physical Sciences ; Pneumonia ; Psoriasis ; Pulmonary fibrosis ; Research and Analysis Methods ; Respiratory diseases ; Risk analysis ; Risk factors ; Statistical analysis ; Steroids</subject><ispartof>PloS one, 2021-01, Vol.16 (1), p.e0245284-e0245284</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Miyagawa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Miyagawa et al 2021 Miyagawa et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-41db5658e30862172bcc7392a8e8e6b10a9e9e72e5229ddb509b248d0a80c01f3</citedby><cites>FETCH-LOGICAL-c692t-41db5658e30862172bcc7392a8e8e6b10a9e9e72e5229ddb509b248d0a80c01f3</cites><orcidid>0000-0001-9507-7454</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790374/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790374/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33411857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kuwana, Masataka</contributor><creatorcontrib>Miyagawa, Hanae</creatorcontrib><creatorcontrib>Hara, Hiromichi</creatorcontrib><creatorcontrib>Araya, Jun</creatorcontrib><creatorcontrib>Minagawa, Shunsuke</creatorcontrib><creatorcontrib>Numata, Takanori</creatorcontrib><creatorcontrib>Umezawa, Yoshinori</creatorcontrib><creatorcontrib>Asahina, Akihiko</creatorcontrib><creatorcontrib>Nakagawa, Hidemi</creatorcontrib><creatorcontrib>Kuwano, Kazuyoshi</creatorcontrib><title>Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.
We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT was performed to evaluate DIIP. Serum KL-6 levels were measured before treatment (baseline) and during treatment.
A total of 603 psoriasis patients were treated with anti-IL-17/23 biologics with mean follow-up of 21.1 months. Six patients developed DIIP at mean 14 months after initiation of the therapy. Older age, higher baseline KL-6 value and more frequent pre-existing IPs were associated with development of DIIP by univariate analysis. At the onset of DIIP, elevated serum KL-6 levels with concomitantly increased ground glass opacity (GGO) in Chest CT were demonstrated. DIIP was improved by only cessation of causative agents in five patients but steroid therapy was needed in one patient.
DIIP is a plausible complication of anti-IL-17/23 biologics. Age, baseline KL-6 level and underlying IP could be the risk factors for DIIP development. Serum KL-6 levels and chest CT are useful for not only predicting but also detecting DIIP caused by anti-IL-17/23 biologics.</description><subject>Biological products</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Chest</subject><subject>Complications and side effects</subject><subject>Dermatology</subject><subject>Disease</subject><subject>Health risks</subject><subject>Interleukin 17</subject><subject>Internal medicine</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Monoclonal antibodies</subject><subject>Opacity</subject><subject>Patients</subject><subject>Physical Sciences</subject><subject>Pneumonia</subject><subject>Psoriasis</subject><subject>Pulmonary fibrosis</subject><subject>Research and Analysis Methods</subject><subject>Respiratory diseases</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Steroids</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uL1DAUx4so7rr6DUQLguhDZ3Nrmr4Iy-BlYGDB22tI09OZDJ2km6Revr0Zp7tMZR8kDwknv_M_l-Rk2XOMFphW-HLnRm9VvxichQUirCSCPcjOcU1JwQmiD0_OZ9mTEHYIlVRw_jg7o5RhLMrqPGuXW-WVjuBNiEaH3HW5stEUq3WBq0tC88a43m3SVWFsO2poc2MTnuhoVJ8PFsa9s0Ylcz6oaMDGkP80cZsPwXmjgglPs0ed6gM8m_aL7NuH91-Xn4r19cfV8mpdaF6TWDDcNiUvBVAkOMEVabSuaE2UAAG8wUjVUENFoCSkbhOL6oYw0SIlkEa4oxfZy6Pu0LsgpwYFSViV5GoqcCJWR6J1aicHb_bK_5ZOGfnX4PxGKp_60IPUwHSKWRMiOGs1a5oGaFMxzkRKAjdJ690UbWz20OpUuFf9THR-Y81WbtwPWVU1ohVLAm8mAe9uRghR7k3Q0PfKghuPeZdcYFIm9NU_6P3VTdRGpQKM7VyKqw-i8oqXSOASMZKoxT1UWi3sjU6_qTPJPnN4O3NITIRfcaPGEOTqy-f_Z6-_z9nXJ-wWVB-3wfVjNM6GOciOoPYuBA_dXZMxkodhuO2GPAyDnIYhub04faA7p9vfT_8AVHsD7A</recordid><startdate>20210107</startdate><enddate>20210107</enddate><creator>Miyagawa, Hanae</creator><creator>Hara, Hiromichi</creator><creator>Araya, Jun</creator><creator>Minagawa, Shunsuke</creator><creator>Numata, Takanori</creator><creator>Umezawa, Yoshinori</creator><creator>Asahina, Akihiko</creator><creator>Nakagawa, Hidemi</creator><creator>Kuwano, Kazuyoshi</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9507-7454</orcidid></search><sort><creationdate>20210107</creationdate><title>Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis</title><author>Miyagawa, Hanae ; Hara, Hiromichi ; Araya, Jun ; Minagawa, Shunsuke ; Numata, Takanori ; Umezawa, Yoshinori ; Asahina, Akihiko ; Nakagawa, Hidemi ; Kuwano, Kazuyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-41db5658e30862172bcc7392a8e8e6b10a9e9e72e5229ddb509b248d0a80c01f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biological products</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Chest</topic><topic>Complications and side effects</topic><topic>Dermatology</topic><topic>Disease</topic><topic>Health risks</topic><topic>Interleukin 17</topic><topic>Internal medicine</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Monoclonal antibodies</topic><topic>Opacity</topic><topic>Patients</topic><topic>Physical Sciences</topic><topic>Pneumonia</topic><topic>Psoriasis</topic><topic>Pulmonary fibrosis</topic><topic>Research and Analysis Methods</topic><topic>Respiratory diseases</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyagawa, Hanae</creatorcontrib><creatorcontrib>Hara, Hiromichi</creatorcontrib><creatorcontrib>Araya, Jun</creatorcontrib><creatorcontrib>Minagawa, Shunsuke</creatorcontrib><creatorcontrib>Numata, Takanori</creatorcontrib><creatorcontrib>Umezawa, Yoshinori</creatorcontrib><creatorcontrib>Asahina, Akihiko</creatorcontrib><creatorcontrib>Nakagawa, Hidemi</creatorcontrib><creatorcontrib>Kuwano, Kazuyoshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyagawa, Hanae</au><au>Hara, Hiromichi</au><au>Araya, Jun</au><au>Minagawa, Shunsuke</au><au>Numata, Takanori</au><au>Umezawa, Yoshinori</au><au>Asahina, Akihiko</au><au>Nakagawa, Hidemi</au><au>Kuwano, Kazuyoshi</au><au>Kuwana, Masataka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-01-07</date><risdate>2021</risdate><volume>16</volume><issue>1</issue><spage>e0245284</spage><epage>e0245284</epage><pages>e0245284-e0245284</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.
We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT was performed to evaluate DIIP. Serum KL-6 levels were measured before treatment (baseline) and during treatment.
A total of 603 psoriasis patients were treated with anti-IL-17/23 biologics with mean follow-up of 21.1 months. Six patients developed DIIP at mean 14 months after initiation of the therapy. Older age, higher baseline KL-6 value and more frequent pre-existing IPs were associated with development of DIIP by univariate analysis. At the onset of DIIP, elevated serum KL-6 levels with concomitantly increased ground glass opacity (GGO) in Chest CT were demonstrated. DIIP was improved by only cessation of causative agents in five patients but steroid therapy was needed in one patient.
DIIP is a plausible complication of anti-IL-17/23 biologics. Age, baseline KL-6 level and underlying IP could be the risk factors for DIIP development. Serum KL-6 levels and chest CT are useful for not only predicting but also detecting DIIP caused by anti-IL-17/23 biologics.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33411857</pmid><doi>10.1371/journal.pone.0245284</doi><tpages>e0245284</tpages><orcidid>https://orcid.org/0000-0001-9507-7454</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-01, Vol.16 (1), p.e0245284-e0245284 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2476219381 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Biological products Biology and Life Sciences Care and treatment Chest Complications and side effects Dermatology Disease Health risks Interleukin 17 Internal medicine Medical prognosis Medical records Medicine Medicine and Health Sciences Monoclonal antibodies Opacity Patients Physical Sciences Pneumonia Psoriasis Pulmonary fibrosis Research and Analysis Methods Respiratory diseases Risk analysis Risk factors Statistical analysis Steroids |
| title | Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T20%3A30%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20of%20anti-IL-17/23%20biologics-induced%20interstitial%20pneumonia%20in%20patients%20with%20psoriasis&rft.jtitle=PloS%20one&rft.au=Miyagawa,%20Hanae&rft.date=2021-01-07&rft.volume=16&rft.issue=1&rft.spage=e0245284&rft.epage=e0245284&rft.pages=e0245284-e0245284&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0245284&rft_dat=%3Cgale_plos_%3EA650815042%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476219381&rft_id=info:pmid/33411857&rft_galeid=A650815042&rft_doaj_id=oai_doaj_org_article_ce4cb10922864dc4bbbe3b746489e71b&rfr_iscdi=true |